In Vivo Cell Engineering & Gene Editing · Industry updates
Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
CSPC announced initiation of the first Chinese center for SYS6055-003, a Phase 1/2 trial in relapsed or refractory B-cell non-Hodgkin lymphoma. SYS6055 uses lentiviral vectors to generate CD19-targeting CAR-T cells in vivo. The company said recruitment and screening are underway following October clinical-trial authorization. Center initiation does not establish patient dosing, efficacy, or marketing approval.
Azalea reported SITC preclinical findings for its dual-vector in vivo CAR-T platform, combining targeted CRISPR-Cas9 delivery with AAV-mediated CAR insertion at the TRAC locus. The company described leukemia clearance and protection after tumor rechallenge in selected mouse groups, plus dual-antigen and armored designs. These are animal findings, not evidence of efficacy or safety in patients.
Intellia's third-quarter update reports completed enrollment in the Phase 3 MAGNITUDE-2 trial of nexiguran ziclumeran for hereditary ATTR amyloidosis with polyneuropathy, exceeding the target of 60 randomized patients. The company also described commercial preparations for lonvoguran ziclumeran in hereditary angioedema, ahead of its March 10, 2027 FDA target action date. Approval remains pending.
Precision BioSciences said an independent safety board endorsed additional dosing in the Phase 1/2 FUNCTION-DMD study after reviewing the first PBGENE-DMD recipient's eight-week observation period. No serious adverse events or adverse events of special interest were reported in that patient. The AAV-delivered gene-editing program remains investigational; this single-patient review does not establish efficacy or broader safety.
Precision BioSciences reported updated PBGENE-HBV Phase 1 data covering 25 patients and 59 administrations. The company described pgRNA loss and liver-biopsy evidence of cccDNA reduction at the expected go-forward dose of 0.4 mg/kg, with no dose-limiting toxicities reported. It plans Phase 2 evaluation, including assessment after nucleos(t)ide analog withdrawal; viral cure has not been established.
A Nature study describes FAST gene circuits that exploit cancer-associated ribosomal frameshifting to conditionally express gasdermin D and trigger pyroptosis. According to the original abstract, systemic AAV9 delivery produced tumor regression and immune activation in mouse colorectal and pancreatic cancer models, with synergy alongside checkpoint blockade. These are cell and animal findings, not human clinical evidence.
Umoja announced four accepted ASH presentations, including clinical data from investigator-initiated studies of CD22-directed UB-VV400 in B-cell malignancies and UB-VV410 in lupus. Separate trial-in-progress posters concern UB-VV400 and BCMA/GPRC5D-directed UB-VV500. The announcement schedules December presentations rather than providing numerical response or safety results from those studies.
Tessera announced three preclinical presentations for the December 2026 ASH meeting. Topics include targeted LNP delivery for functional CAR-T generation in nonhuman primates and in vivo hematopoietic stem-cell editing for sickle cell disease. This is a company announcement of upcoming presentations, not a peer-reviewed publication or evidence of clinical benefit.
Precision BioSciences updated its ARCUS in vivo editing portfolio in its third-quarter report. The company described ongoing ELIMINATE-B evaluation of PBGENE-HBV and the Phase 1/2 FUNCTION-DMD study of PBGENE-DMD, which uses AAV delivery. Planned data releases and management expectations should be distinguished from completed clinical outcomes.
FDA announced final guidance on potency assurance for cellular and gene therapies on November 2. Its recommendations integrate manufacturing-process design, material and process controls, in-process testing, and lot-release potency assays. The agency emphasizes product-specific, risk-based strategies across development and commercialization; this is final guidance, not approval of any individual therapy.
A polymer-lipid carrier incorporating arginine-modified oligoethylenimine combined T-cell activation with mRNA delivery without an added targeting ligand. The formulation favored splenic delivery and engaged PI3K-AKT-mTOR signaling. FAP-CAR mRNA generated functional CAR T cells in experimental cancer and fibrosis settings. These are preclinical results; the article also has a subsequent publisher correction that should accompany interpretation.
Continue your research
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.
